BioNTech SE (22UA.F) XETRA

90.50

+3(+3.43%)

Updated at September 09 08:25AM

Currency In EUR

BioNTech SE

Address

An der Goldgrube 12

Mainz, 55131

Germany

Phone

49 6131 9084 0

Sector

Healthcare

Industry

Biotechnology

Employees

6772

First IPO Date

October 11, 2019

Key Executives

NameTitlePayYear Born
Dr. Ugur Sahin M.D.Co-Founder, Chief Executive Officer & Chair of the Management Board965,0001965
Dr. Ozlem Tureci M.D.Co-Founder, Chief Medical Officer & Member of Management Board772,0001967
Mr. Jens H. HolsteinChief Financial Officer & Member of Management Board777,0001963
Dr. Sierk Poetting Ph.D.MD, Chief Operating Officer & Member of Management Board791,0001973
Mr. Ryan RichardsonChief Strategy Officer, MD & Member of Management Board799,0001979
Dr. James Timothy Patrick Ryan Ph.D.Chief Legal & Business Officer & Member of the Management Board881,0001975
Ms. Annemarie HanekampChief Commercial Officer & Member of Management Board1.73M1980
Ms. Beate BernsSenior Vice President of Global Human Resources0N/A
Ms. Lisa BirringerSenior Vice President of Global Financial Reporting & Accounting0N/A
Mr. Zach TaylorSenior Vice President of Corporate Development & Strategy0N/A

Description

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, a preclinical stage product for non-small cell lung cancer. It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase 1a/1b clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 to treat solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II clinical trial to treat solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody in Phase II clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.